Emerging Treatment Options for Pustular Psoriasis

Complimentary

Released on 5/31/22
Expires on 5/31/23

Categories: , , , , , , , , , , ,
Severely inflamed and scaly skin on a person's arm.

Start Activity

Program Description

Pustular psoriasis (PP) can be classified as either generalized pustular psoriasis (GPP) or localized pustular psoriasis. GPP is an uncommon and life-threatening skin disease characterized by a widespread eruption of pustules overlying erythematous plaques, usually accompanied by fever and malaise. The lethal complications of GPP include sepsis, acute respiratory distress syndrome, and renal dysfunction. Conventional treatments, including retinoids, cyclosporine, and methotrexate, have shown efficacy in GPP patients; however, these drugs present a risk of toxicity. Several clinical trials have studied the efficacy and safety of biologics for treating PP. Despite the benefits of biologics, multiple potential adverse effects have been reported, particularly infections, especially reactivation of hepatitis B and C virus, latent tuberculosis, herpes zoster, and malignancy. One of the key reasons is initial misdiagnosis – GPP can often be mistaken for an infection, which may lead to incorrect treatment or a delay in referral to a specialist. Due to its rarity, many healthcare professionals do not have experience and knowledge of PP or GPP; therefore, improved recognition and understanding of PP or GPP is essential to helping patients receive a prompt diagnosis and effective disease management.

Intended Audience

Dermatologists, primary care physicians, physician assistants, nurse practitioners, and nurses

Commercial Supporter

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

  • Summarize the pathophysiology of pustular psoriasis (PP), including how it differs from that of generalized plaque psoriasis (GPP) and potential pathways for therapeutic targets
  • Evaluate patients with PP based on clinical manifestations, diagnostic criteria, and disease severity
  • Identify the clinical profiles and mechanisms of action of new and emerging biological treatment options and management of adverse events in patients with PP

Accredited Providers

This activity is provided by Amedco, a CME/CE company, and MedNet

      

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MetNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Designation Statement

Amedco LLC designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) Credit Designation

Designation Statement

Amedco LLC designates this activity for a maximum of 1.25 ANCC contact hours.

Additional Credit Information

Note to Physician Assistants
PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME or a recognized state medical society

Note to Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.

Conflicts of Interest Policy

It is the policy of Amedco and MedNet to ensure activity content is balanced, independent, objective, and based on scientific best evidence. All persons in a position to control content (i.e., course director, planning committee member, and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to his/her presentation content.

Every person in a position to control content reported he/she does not have any relevant financial relationships with the industry (relative to the content of his/her presentation) to disclose.

Planners’ and Managers’ Disclosures

Mark Lebwohl, MD, discloses the following::
Employee: Mount Sinai
Research Funds: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc.
Consultant: Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Arrive Technologies, Avotres Therapeutics, BiomX, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Dr. Reddy’s Laboratories, Evelo Biosciences, Evommune, Inc., Facilitatation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexima Ltd., LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, and Verrica.

Kamatham A. Naidu, PhD (MedNet) has no relevant financial relationships

Disclosure of Unlabeled Use

It is the policy of Amedco and MedNet to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she would notify the audience if/when the discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Faculty

Mark Lebwohl, MD
Dean for Clinical Therapeutics
Icahn School of Medicine at Mount Sinai
Chairman Emeritus Kimberly and Eric J. Waldman
Department of Dermatology
New York, NY

Dr. Lebwohl discloses that he is an employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc.

Dr. Lebwohl discloses that he is a consultant of Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Arrive Technologies, Avotres Therapeutics, BiomX, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Dr. Reddy’s Laboratories, Evelo Biosciences, Evommune, Inc., Facilitatation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexima Ltd., LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, and Verrica.

Instructions

In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

For information about the accreditation of this program, please contact Sheryl Morgan (651-789-3730; email: Sheryl@AmedcoEmail.com

Privacy Policy

Amedco observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

Webcast

Time to Complete: 1.25 hours

Released: May 31, 2022

Expires: May 31, 2023

Maximum Credits:
1.25 / AMA PRA Category 1 Credit(s)TM
1.25 / ANCC Contact Hour(s)

Related products